H.R. 6130House119th Congress (2025-2027)In Committee

ASAP Act

Introduced November 19, 2025

AI-Generated Summary

Updated December 4, 2025 at 4:01 PM UTC

The ASAP Act amends the Social Security Act to require Medicare to cover early‑detection screening tests for Alzheimer’s disease and related dementias. The coverage applies to blood‑based or equivalent tests that are FDA‑cleared or approved and become available on or after January 1, 2028. The change is aimed at Medicare beneficiaries who may benefit from early diagnosis of dementia.

Key Provisions

  • Adds a new category (KK) to Medicare’s covered services list for Alzheimer’s and related‑dementia early‑detection screening tests.
  • Defines an “early detection screening test” as a blood‑based genomic sequencing test or an equivalent test (including single‑analyte, cell‑free nucleic acid, multiplex panel, whole‑genome/exome/transcriptome, protein expression, or related imaging) that is cleared or approved under the FDA’s 510(k), 513(f)(2), or 515 pathways.
  • Specifies that these tests must be available on or after January 1, 2028 to be covered.
  • Amends Medicare payment rules to include these screening tests as reimbursable services under the existing payment provisions.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

3 earlier actions
HouseCommittee Latest Action

Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0.

September 16, 2026

View full timeline
HouseIntro Referral

Introduced in House

November 19, 2025

HouseIntro Referral

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

November 19, 2025

HouseCommittee

Committee Consideration and Mark-up Session Held

September 16, 2026

HouseCommittee

Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0.

September 16, 2026

Floor Debate

1 member

What members said about H.R. 6130 on the floor

1 Republican
Monica De La Cruz
Rep. Monica De La CruzR-TX-15 · Dec 16, 2025

Under clause 7 of rule XII, sponsors were added to public bills and resolutions, as follows: H.R. 116: Mr. Jack. H.R. 154: Mr. Landsman. H.R. 158: Mr. Landsman. H.R. 220: Ms. Escobar. H.R. 251: Mr.…

Monica De La Cruz
Rep. Monica De La CruzR-TX-15 · Jul 9, 2026

Under clause 7 of rule XII, sponsors were added to public bills and resolutions, as follows: H.R. 7: Mr. Van Epps. H.R. 138: Ms. Norton, Ms. Hoyle of Oregon, and Mr. Calvert. H.R. 491: Ms. Wilson of…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued November 19, 2025

I

119th CONGRESS

1st Session

H. R. 6130

IN THE HOUSE OF REPRESENTATIVES

November 19, 2025

Mr. Buchanan (for himself and Mr. Tonko) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.

1.

Short title

This Act may be cited as the Alzheimer’s Screening and Prevention Act of 2025 or the ASAP Act.

2.

Medicare coverage of Alzheimer’s disease and related dementias early detection screening tests

(a)

Coverage

Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended—

(1)

in subsection (s)(2)—

(A)

in subparagraph (JJ), by striking the semicolon at the end and inserting ; and; and

(B)

by adding at the end the following new subparagraph:

(KK)

Alzheimer’s disease and related dementias early detection screening tests (as defined in subsection (nnn));

; and

(2)

by adding at the end the following new subsection:

(nnn)

Alzheimer’s disease and related dementias early detection screening tests

The term Alzheimer’s disease and related dementias early detection screening test means a test furnished to an individual for the detection of the pre-symptomatic and early stage of Alzheimer’s disease or related dementias on or after January 1, 2028, that—

(1)

is cleared under section 510(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and

(2)

is—

(A)

a genomic sequencing blood or blood product test; or

(B)

such other equivalent test, including a single-analyte test, blood test analysis of cell-free nucleic acids, multiplex panel test, whole genome sequencing, protein expression, whole exome, whole transcriptome, and medical imaging (which are based on blood, blood products, tissue, urine or other biospecimen), as the Secretary determines appropriate in providing results comparable to those obtained with a test described in subparagraph (A).

.

(b)

Payment

Section 1833(h)(1)(A) of the Social Security Act (42 U.S.C. 1395l(h)(1)(A)) is amended by inserting Alzheimer’s disease and related dementias early detection screening tests under section 1861(nnn) and after including.